Bernstein Harold 4

What Happened

• Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics, exercised 15,000 stock option shares (reported as an "M" transaction) at $10.42 per share (cost $156,300) on 2026-04-01 and sold a total of 15,000 shares that same day in three open‑market transactions for combined proceeds of $441,904.
• The filing also reports a separate 15,000‑share derivative disposition at $0.00 (listed as a derivative disposal). The Form 4 does not provide further detail about that zero‑dollar line beyond the transaction code.

Key Details

• Transaction date: 2026-04-01; Form 4 filed 2026-04-02 (timely filing).
• Option exercise: 15,000 shares @ $10.42 (total $156,300).
• Open‑market sales: 11,352 shares @ $29.24 (weighted avg; range $28.77–$29.75), 3,348 shares @ $30.06 (range $29.77–$30.50), and 300 shares @ $31.07 (range $30.80–$31.22) — total proceeds $441,904.
• Additional line: 15,000 shares reported disposed as a derivative at $0.00 (no cash reported).
• Shares owned after the transactions: not disclosed in the provided filing excerpt.
• Footnotes: sales were effected under a Rule 10b5‑1 trading plan adopted Sept 29, 2025 (F1). Vesting schedule for the option award is noted (1/4 on Oct 3, 2023, then monthly 1/48th) (F5). Weighted‑average pricing details provided in F2–F4.

Context

• This was an exercise followed by immediate open‑market sales (common practice to monetize vested option shares). The insider paid the exercise price ($156.3K) and realized gross sale proceeds of ~$442K the same day.
• The zero‑dollar derivative disposition is shown on the form but not explained in the filing; Form 4s sometimes include such lines for net settlements or withholding, but the filing here does not specify the reason.